• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    AeroClean Announces Appointment of Timothy J. Scannell to Board of Directors

    5/12/22 1:00:00 PM ET
    $AERC
    $NVCR
    $PODD
    $RNLX
    Environmental Services
    Utilities
    Medical/Dental Instruments
    Health Care
    Get the next $AERC alert in real time by email

    PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies ("AeroClean" or the "Company") (NASDAQ:AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the "Board"). On May 11, 2022, the Board appointed Mr. Scannell as a new director on the Board, chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee.

    Mr. Scannell brings over 30 years of experience and success delivering market-leading results from his leadership roles at Stryker Corporation (NYSE:SYK) ("Stryker"), one of the world's leading medical technology companies. Mr. Scannell served as President and Chief Operating Officer of Stryker between 2018 and 2021, overseeing all of Stryker's commercial businesses and regions globally. Prior to this, he served as group president for Stryker's MedSurg & Neurotechnology businesses for ten years. Mr. Scannell currently serves as a director and non-executive chairman of the Board of Directors for Insulet Corporation (NASDAQ:PODD) and is a director on the boards of Novocure Limited (NASDAQ:NVCR), Renalytix plc (NASDAQ:RNLX) and Collagen Matrix, Inc.

    "Tim Scannell is a medical technology industry veteran with vast experience and a tremendous track record of success. He drove market leading sales and supported Stryker's top tier M&A results during his time at Stryker. He will be a great addition to our Board," said Jason DiBona, AeroClean's Chief Executive Officer. "Tim's interest in joining our Board and helping advance our mission is a testament to our Company's vision. I welcome Tim to the team and look forward to his contributions to the success of AeroClean."

    "I am proud to join the Board of AeroClean. I look forward to supporting and advancing AeroClean's mission of keeping life going with healthy, safe air solutions," said Mr. Scannell. "I am energized by AeroClean's mission, impressed by their board and management team, and enthusiastic about the Company's opportunity to build a great business with tremendous impact on millions of lives in the years to come."

    About AeroClean Technologies

    AeroClean is a pathogen elimination technology company on a mission to keep work, play and life going—with continuous air sanitization products called Pūrgo™ (pure-go). We create solutions for hospitals, offices, and many shared spaces as well as elevators and more. Pūrgo™ products feature SteriDuct™, a proprietary technology developed by our best-in-class aerospace engineers, medical scientists and innovators. Powered by SteriDuct™, our solutions are medical grade, eradicating viral, fungal and bacterial airborne pathogens. Our purpose is simple: to never stop innovating solutions that keep people healthy and safe, so life never stops. Learn more at aeroclean.com.

    Media Contact

    Drew Tybus

    [email protected]

    Investor Relations Contacts

    Ryan Tyler

    Chief Financial Officer, AeroClean

    [email protected]

    Brian Pinkston

    MATTIO Communications

    [email protected]



    Primary Logo

    Get the next $AERC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AERC
    $NVCR
    $PODD
    $RNLX

    CompanyDatePrice TargetRatingAnalyst
    Insulet Corporation
    $PODD
    10/21/2025$370.00Buy
    Stifel
    Stryker Corporation
    $SYK
    9/18/2025$420.00Neutral
    Rothschild & Co Redburn
    Insulet Corporation
    $PODD
    9/8/2025$365.00Outperform
    Oppenheimer
    NovoCure Limited
    $NVCR
    7/25/2025$14.50Overweight → Equal Weight
    Wells Fargo
    NovoCure Limited
    $NVCR
    7/8/2025$30.00Buy
    Ladenburg Thalmann
    Insulet Corporation
    $PODD
    6/16/2025$365.00Buy
    Truist
    Insulet Corporation
    $PODD
    5/30/2025$380.00Buy
    Goldman
    Insulet Corporation
    $PODD
    5/13/2025$350.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $AERC
    $NVCR
    $PODD
    $RNLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel resumed coverage on Insulet with a new price target

    Stifel resumed coverage of Insulet with a rating of Buy and set a new price target of $370.00

    10/21/25 7:21:42 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Rothschild & Co Redburn initiated coverage on Stryker with a new price target

    Rothschild & Co Redburn initiated coverage of Stryker with a rating of Neutral and set a new price target of $420.00

    9/18/25 8:44:39 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Oppenheimer resumed coverage on Insulet with a new price target

    Oppenheimer resumed coverage of Insulet with a rating of Outperform and set a new price target of $365.00

    9/8/25 8:52:38 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Pease Flavia was granted 11,708 shares, increasing direct ownership by 323% to 15,337 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    10/2/25 4:19:14 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    SVP, Global Operations Singh Prem sold $238,726 worth of shares (687 units at $347.49), decreasing direct ownership by 17% to 3,456 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    9/9/25 4:19:06 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    SVP, Reg, Quality & Compliance Cousin Laetitia sold $278,002 worth of shares (797 units at $348.81) and exercised 797 shares at a strike of $241.10 (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    9/9/25 4:16:29 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress

    Novocure (NASDAQ:NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European Association of Neuro-Oncology (EANO) Meeting, being held October 16-19 in Prague, Czech Republic, and the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21 in Berlin, Germany. At the EANO 2025 Meeting, Novocure will present pre-clinical data highlighting the potential of Tumor Treating Fields (TTFields) therapy to enhance radiosensitivity of glioblastoma cells by downregulating DNA repair pathways. At the ESMO Congress 2025, Novocure will present a post-hoc analysis of its successful Phase 3 PANOVA-3 trial, which evaluated the use of

    10/15/25 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Stryker to Feature Expanding Trauma Portfolio at the Orthopaedic Trauma Association Annual Meeting 2025

    Stryker (NYSE:SYK), a global leader in medical technologies, will showcase new additions to its trauma offerings at the Orthopaedic Trauma Association (OTA) Annual Meeting, October 15–18, in Phoenix, Ariz. (booth #601). The company will highlight upcoming expansions to its nailing and plating platforms. For more than 80 years, Stryker has collaborated with surgeons to help design their products and advance its trauma offerings through continuous innovation in nailing and plating. Building on that legacy, the Pangea platform and T2 Alpha system have been designed to simplify instrumentation, enhance stability and provide greater flexibility in managing complex fractures. The new T2 Alpha

    10/14/25 8:10:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Insulet to Host Investor Day on November 20, 2025

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's Acton, Massachusetts headquarters on Thursday, November 20, 2025. The Investor Day will include presentations from the management team highlighting the Company's longer-term strategic priorities, including market opportunities, innovation roadmap, as well as its longer-term financial outlook. Manufacturing tours will be available following the conclusion of the formal presentations, which are expected to begin at 9:00 a.m. (ET) and conclude at approximately 12:30 p.m. (ET). The Company invites in

    10/10/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    SEC Filings

    View All

    Insulet Corporation filed SEC Form 8-K: Leadership Update

    8-K - INSULET CORP (0001145197) (Filer)

    9/16/25 7:05:56 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    NovoCure Limited filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NovoCure Ltd (0001645113) (Filer)

    9/15/25 7:00:10 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Insulet Corporation

    144 - INSULET CORP (0001145197) (Subject)

    9/8/25 1:31:47 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Leadership Updates

    Live Leadership Updates

    View All

    Insulet to Host Investor Day on November 20, 2025

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's Acton, Massachusetts headquarters on Thursday, November 20, 2025. The Investor Day will include presentations from the management team highlighting the Company's longer-term strategic priorities, including market opportunities, innovation roadmap, as well as its longer-term financial outlook. Manufacturing tours will be available following the conclusion of the formal presentations, which are expected to begin at 9:00 a.m. (ET) and conclude at approximately 12:30 p.m. (ET). The Company invites in

    10/10/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Announces CFO Transition

    Flavia Pease Appointed Chief Financial Officer Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Flavia Pease will succeed Ana Maria Chadwick as Executive Vice President, Chief Financial Officer, effective September 30, 2025. Ms. Chadwick will become a Senior Advisor to Insulet to ensure a smooth transition. "I want to personally thank Ana, who has provided steady and thoughtful leadership for Insulet during a period of significant growth," said Ashley McEvoy, Insulet President and Chief Executive Officer. "She has been instrumental in strengthening our financial

    9/16/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Elevates Eric Benjamin to Chief Operating Officer

    Company Further Strengthens Leadership Team with Appointment of Chief Growth Officer Manoj Raghunandanan Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Eric Benjamin to Chief Operating Officer effective immediately. The Company also announced the appointment of Manoj Raghunandanan as Chief Growth Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250825870386/en/Eric Benjamin, Insulet Chief Operating Officer In this expanded role, Mr. Benjamin will lead Insulet's end-to-end growth and

    8/25/25 5:00:00 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Financials

    Live finance-specific insights

    View All

    Novocure to Report Third Quarter 2025 Financial Results

    Novocure (NASDAQ:NVCR) will report financial results for the third quarter 2025 on October 30, 2025, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the company's financial results for the three- and nine-month periods that ended September 30, 2025. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure's website, www.

    10/1/25 7:00:00 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Stryker declares an $0.84 per share quarterly dividend

    Portage, Michigan, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable October 31, 2025, to shareholders of record at the close of business on September 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more

    8/7/25 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1)

    Raising Full Year Revenue and Adjusted Operating Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2025. Second Quarter Financial Highlights: Revenue of $649.1 million, up 32.9%, or 31.3% in constant currency, exceeds the high end of the Company's guidance range of 26.0% in constant currency Total Omnipod revenue of $639.0 million, up 33.0%, or 31.4% in constant currency U.S. Omnipod revenue of $453.2 million, up 28.7% International Omnipod revenue of $185.8 million, up 45.0%, or 38.8% in cons

    8/7/25 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Cordova Ashley bought $996,859 worth of Ordinary Shares (81,550 units at $12.22), increasing direct ownership by 23% to 437,569 units (SEC Form 4)

    4 - NovoCure Ltd (0001645113) (Issuer)

    9/8/25 7:10:52 AM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Brackmann Christoph bought $231,800 worth of Ordinary Shares (20,000 units at $11.59), increasing direct ownership by 17% to 141,150 units (SEC Form 4)

    4 - NovoCure Ltd (0001645113) (Issuer)

    7/30/25 4:33:06 PM ET
    $NVCR
    Medical/Dental Instruments
    Health Care

    EVP, CFO & Treasurer Chadwick Ana Maria bought $20,600 worth of shares (100 units at $206.00), increasing direct ownership by 0.76% to 13,314 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    8/29/24 4:17:26 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $AERC
    $NVCR
    $PODD
    $RNLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Insulet Corporation

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    11/12/24 12:53:28 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Insulet Corporation

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    10/7/24 11:37:08 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Renalytix plc

    SC 13D/A - Renalytix plc (0001811115) (Subject)

    10/2/24 8:05:02 PM ET
    $RNLX
    Medical Specialities
    Health Care